News – Ypsomed Delivery Systems

YpsoMate's platform approach is paying off

Several customers have recently launched their autoinjectors based on our YpsoMate platform product technology on the market. Customers value the fast product customisation as well as the individual design possibilities. End users appreciate its user-friendliness.

YpsoMate autoinjector
Our autoinjector YpsoMate has been launched on the market by a number of renowned pharma and biotech companies.

There is increasing demand for easy to use injection devices for home application. Our platform product YpsoMate meets exactly this demand. The autoinjector platform with a filling volume range of 0.2 ml to 1.0 ml is very user-friendly thanks to its 2-step concept. The less frequent the drug has to be injected, the more important the user-friendliness of the device. The drugs launched in YpsoMate over the last few months are used for the treatment of severe asthma, rheumatoid arthritis, multiple sclerosis and sexual dysfunction.

Benefits of self-medication at home

Self-medication has several advantages. Mainly, the patients’ life quality is improved as they do not have to go to their doctor or to the hospital each time that they receive an injection. This significantly reduces health care costs.

Customised solutions

For our injection systems, we rely on platform technologies. Our customers benefit from a short customisation phase and a proven product. The design of the customer-specific YpsoMate variant can be adapted according to customers' requirements. This enables customers to launch an injection system on the market, which is tailored to their drug and that stands out from competitors’ products.

YpsoMate with higher filling volume

In addition to our YpsoMate platform with a maximum filling volume of 1.0 ml, we have developed and industrialised YpsoMate 2.25 which offers a maximum filling volume of 2.25 ml. The YpsoMate 2.25 is suitable for drugs that need to be injected in larger volumes. The first customer-specific variant of YpsoMate 2.25 will soon receive market approval.

YpsoMate 2.25 fully automated manufacturing Ypsomed has invested in fully automated manufacturing, resulting in a product of continuous high quality.

Both the YpsoMate and the YpsoMate 2.25 autoinjector platforms are produced on fully automated production lines at our sites in Switzerland.

More information:

Go Back